Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cronos GroupFRA:7CI +3.27%87 Cash Ratio is 14.14 as of Jun. 2026, which is 5% above its 10-year median of 13.52. GuruFocus rates FRA:7CI with a GF Score™ of 87/100 and a GF Value™ of €3.18 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 971 Drug Manufacturers companies, Cronos Group ranks better than 97.53% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Cronos Group Cash Ratio Related Terms
Cronos Group Cash Ratio Historical Data
* Premium members only.
The historical data trend for Cronos Group's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cronos Group's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (FRA:7CI) has a Cash Ratio of 14.14 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cronos Group and its competitors. This is near median its historical median of 13.52. Over the past decade, Cronos Group's Cash Ratio has ranged from 0.45 to 38.41. According to the industry distribution chart, Cronos Group ranks #24 out of 971 companies in the Drug Manufacturers industry, placing it in the top 2.5%.
Is Cronos Group's Cash Ratio too high?
Cronos Group's current Cash Ratio of 14.14 is near median its 10-year median of 13.52. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 38.41. The Drug Manufacturers industry median Cash Ratio is 0.59. Cronos Group's value of 14.14 is 2296.6% above this industry median. Based on the distribution chart, Cronos Group ranks #24 out of 971 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cronos Group has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #24 out of 971 companies for Cash Ratio. This places Cronos Group in the top 3% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.59. Cronos Group's value of 14.14 is 2296.6% above this benchmark. Historically, Cronos Group's own Cash Ratio has ranged from 0.45 to 38.41 over the past decade. While the company's 10-year median is 13.52 vs. the industry median of 0.59, Cronos Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.59, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current Cash Ratio of 14.14 is 2296.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current Cash Ratio is 14.14, which is near median its own 10-year median of 13.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (FRA:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.18, compared to a current price of €2.71 — trading 14.7% below its estimated fair value. The current Cash Ratio is 14.14, which is near median its 10-year median of 13.52 and 2296.6% above the Drug Manufacturers industry median of 0.59. Cronos Group's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Cronos Group (FRA:7CI), the current Cash Ratio is 14.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (FRA:7CI) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of €2.71 is trading 14.7% below its estimated GF Value™ of €3.18.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for FRA:7CI:
Cash Ratio: 14.14 (near median its 10-year median of 13.52)
GF Value™: €3.18 vs. price of €2.71 (14.7% below fair value)
Industry Position: 2296.6% above the Drug Manufacturers median (#24 of 971)
No single metric tells the full story. See the FRA:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
87GF Score
Get the complete analysis for FRA:7CI
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7CI has been successfully added to your 
